Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a multinational pharmaceutical and life sciences company based in Germany, recently had its CEO, Bill Anderson, accompany German Chancellor Olaf Scholz on a high-profile visit to China. In a brief interview with Xinhua, Anderson emphasized Bayer’s dedication to developing innovative drugs and its commitment to the Chinese market, stating his reasons for joining Scholz as an opportunity to engage with Chinese leaders and deepen market insights.
With approximately 8,000 employees in China, Bayer views the market as a strategic priority for its three core business segments: pharmaceuticals, crop sciences, and consumer health. Anderson announced several new investments in China, including a forthcoming open-innovation platform in Shanghai focused on cell and gene therapy, a new crop science facility in Hangzhou, and a new consumer health innovation center in Shanghai.
Anderson expressed optimism about China’s market prospects, as quoted by Xinhua: “China’s commitment to high-quality development is very encouraging. I’m sure investment will continue in the future.” Reflecting this positive outlook, Bayer has been an active participant in the multinational market, recently signing partnerships with Jixing Pharmaceuticals for cardiovascular and ophthalmology therapeutics and with Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550) for digestive enzyme product development.- Flcube.com
